Leg Ischemia and Aortoiliac Disease

Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia

Soga Y, Iida O, Hirano K, et al (Kokura Memorial Hosp, Kitakyushu, Japan; Kansai Rosai Hosp, Amagasaki, Japan; Saiseikai Yokohama-city Eastern Hosp, Japan; et al) J Vasc Surg 54:1659–1667, 2011^§

Abstract

Background

Cilostazol reduces restenosis and repeat revascularization after endovascular therapy (EVT) in claudicant patients with femoropopliteal lesions. However, the efficacy of cilostazol in patients with critical limb ischemia (CLI) is unclear. Therefore, we investigated the effect of cilostazol on outcomes in patients with CLI.

Methods

From January 2004 to December 2009, 618 patients (30.8% women, 356 treated with cilostazol, 72.4 ± 7.3 years old) with CLI underwent EVT for de novo infrainguinal lesions. Their data were retrospectively analyzed. The primary outcome measure was amputation-free survival (AFS), The secondary outcome measures were overall survival, limb salvage, freedom from repeat revascularization, and freedom from surgical conversion. Mean follow-up was 21 ± 14 months.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Function Testing of Platelets and Long-term Outcome of Patients with Peripheral Arterial Disease Undergoing Transluminal Angioplasty
2. of Hypoxia-Inducible Factor-1α Gene Therapy on Walking Performance in Patients With Intermittent Claudication
3. Proximal Endografting With Distal Bare-Metal Stenting for Management of Aortic Dissection
4. and Removal of Inferior Vena Cava Filters: National Trends in the Medicare Population

Stay updated, free articles. Join our Telegram channel

Join